As part of their 3rd quarter 2008 earnings announcement, Invitrogen noted that they have purchased early stage single molecule sequencing startup Visigen for $20 million.
Visigen's technology centers on the use of a labeled polymerase and nucleotides which produce an intermolecular FRET fluorescence event during incorporation. They were recently granted what appears to be a key patent in this area.
Applied Biosystems had previously made an equity investment in Visigen.
Comment